Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma.

Saved in:
Bibliographic Details
Title: Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma.
Authors: Hornsteiner F; Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria., Vierthaler J; Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria., Strandt H; Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria., Resag A; Institute of Immunology, Faculty of Medicine Carl Gustav Carus, Dresden University of Technology, Dresden, Germany., Fu Z; Malaghan Institute of Medical Research, Wellington, New Zealand., Ausserhofer M; Department of Molecular Biology, Digital Science Center (DiSC), University of Innsbruck, Innsbruck, Austria., Tripp CH; Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria., Dieckmann S; Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria., Kanduth M; Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria., Farrand K; Malaghan Institute of Medical Research, Wellington, New Zealand., Bregar S; Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria., Nemati N; Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria., Hermann-Kleiter N; Institute of Cell Genetics, Department for Genetics and Pharmacology, Medical University of Innsbruck, Innsbruck, Austria., Seretis A; Institute for Biomedical Aging Research, University of Innsbruck, Innsbruck, Austria., Morla S; Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria., Mullins D; Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA., Finotello F; Department of Molecular Biology, Digital Science Center (DiSC), University of Innsbruck, Innsbruck, Austria., Trajanoski Z; Biocenter, Institute of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria., Wollmann G; Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria., Ronchese F; Malaghan Institute of Medical Research, Wellington, New Zealand., Schmitz M; Institute of Immunology, Faculty of Medicine Carl Gustav Carus, Dresden University of Technology, Dresden, Germany., Hermans IF; Malaghan Institute of Medical Research, Wellington, New Zealand., Stoitzner P; Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria patrizia.stoitzner@i-med.ac.at.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Apr 17; Vol. 12 (4). Date of Electronic Publication: 2024 Apr 17.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2051-1426
DOI:10.1136/jitc-2023-008606